His Majesty the King is the patron of the Norwegian Cancer Society

Members of the royal family have been excellent ambassadors for the Norwegian Cancer Society since 1948, when King Haakon VII became the society’s first patron. King Harald has been the Norwegian Cancer Society’s patron since 2005. He participates in the society’s annual award of the King Olav V cancer research prize in June. The prize was established on 29 April 1992, in memory of King Olav V, and is awarded to a cancer researcher – or a cancer research team – that has helped to promote the quality and scope of Norwegian cancer research.
Living with cancer

When a person is diagnosed with cancer, prospects for the future will suddenly seem limited. Our goal is to provide many more people with hope for the future, and to add more days to their lives, but also more life to their days.

We need to raise greater awareness of the major challenges society faces due to the large number of people in Norway living with cancer. We will continue our efforts towards making it possible for people to live good, active and long lives – with cancer.

The Norwegian Cancer Society is committed to working for better treatment and follow-up of this patient group. Our research efforts have resulted in improved, life-extending treatment, particularly in the field of immunotherapy. By strengthening our own services – with cancer coordinators, the Varde Centres, Theme cafés, and Treffpunkt (Meeting Place) – we will enable a growing number of people with incurable cancer to find a community and the courage to lead their lives.

In 2015, the theme Living with Cancer has influenced a large part of the Norwegian Cancer Society’s activities and communication. This was the theme of the campaign “Krafttak mot kreft” (Combat Against Cancer) last winter, and also the primary focus of the Pink Ribbon campaigns over the past two years. This will continue to be a key priority, and the reason why is clear: Improved diagnostics have provided cures for, or prolonged the lives of a growing number of cancer patients. Approximately 242,000 Norwegians are alive today due to cancer diagnostics and treatment, and this number is likely to rise in the years to come.
Chairman
Dr. Gunn-Elin Aa. Bjørneboe, M.D.

University Director at the University of Oslo. Former researcher with the Institute for Nutrition Research at the University of Oslo, and has held professorships at the University of Oslo and University of Tromsø. She was previously the Director of the Norwegian National Nutrition Council, after which she was Assistant Director with the Directorate of Health and Social Services, before becoming University Director.

Deputy Chair
Carl Otto Løvenskiold
CEO

Civil Economist/MBA. Owner and CEO of Løvenskiold-Vækerø AS, a family business. Former President of Virke (formerly HSH) and is currently a Board Member of Norway Trade Fairs, “Bygg Reis Deg” (Building Exhibition), Bergens Høim and EDRA (European DIY Retail Association).

Dr. Tone Nordøy, M.D.
Senior Physician

Specialist in Oncology (specifically the study of tumours) and radiation therapy. Head of the Department of Oncology at the University Hospital of Northern Norway in Tromsø.

Dr. Lars A. Akslen
M.D.

Professor at the University of Bergen, and Senior Physician at Haukeland University Hospital. Awarded the King Olav V cancer research prize in 2009.

Anine Kierulf,
PhD

Lawyer and researcher at the Norwegian Centre for Human Rights at the University of Oslo. Former advisor for Council of Europe, Senior Attorney with the Schjødt Law Firm, and Judge for the Ringerike District Court.

Grete Wennes
Professor

Professor at Trondheim Business School. Former Senior Researcher with SINTEF Technology and Society, and board member for a number of cultural institutions.

Tord Dale
General Manager

General Manager of Maritime Forum. Former political advisor for several cabinet ministers, including Anne-Grete Strøm-Erichsen with the Department of Health and Care Services. Is a trained nurse and has also studied psychology and political science.

Staff representative
Else Støring

Division Manager for the Cancer Line. Is a trained nurse specialising in oncology, with eleven years of experience as a specialist nurse and head nurse at the Department of Gynaecology at Radiumhospital, and thereafter worked as a clinical research nurse for five years. Began working as an advisor for the Cancer Line in 2005, and has been Division Manager since 2007.
The objectives of the Norwegian Cancer Society include preventing and fighting against cancer, and to improve the quality of life for patients and their families. The Norwegian Cancer Society makes an important contribution to society by fighting cancer on a national and a global level, through research, prevention, information, support, advisory services, and political advocacy.

The Norwegian Cancer Society has its headquarters in Oslo, and district offices in Tromsø, Trondheim, Bergen, Stavanger, Kristiansand, Hamar, Tønsberg and Oslo.

**New strategy for 2016–2019**
The formulation of the Norwegian Cancer Society's new strategy for 2016–2019 has been an important task for the Board in 2015. The primary goals from the previous strategy period have been continued under the following headings: Norway shall become a leading nation in the field of cancer prevention, Norway shall become a leading nation in the field of clinical pathways for cancer patients, and A greater number of cancer patients shall be cured or live longer with cancer.

The phrase “Greater user-oriented cancer care services” is a key theme running through all our activities, and this will be highlighted as a separate goal during the strategy period. The Norwegian Cancer Society shall work towards better utilisation of care technology, wherever this helps to create a better daily life for cancer patients and their families, with added emphasis on older patients who are often suffering from other diseases in addition to cancer. Funding and support from donors, members and volunteers will continue to be crucial in enabling the Norwegian Cancer Society to provide better cancer care for patients in Norway. “Greater commitment to the cancer cause” will therefore be highlighted as a specific goal for the 2016–2019 strategy period.

It is the opinion of the Board that this new strategy will provide a good foundation for further work in the planning and implementation of activities as far as the year 2020.

**Research Year 2015**
Immunotherapy is a form of treatment which received a great deal of attention in 2015. The Norwegian Cancer Society contributed to this through research funding and by arranging a breakfast seminar, attended by both the public and the press.

The Norwegian Cancer Society was a significant source of research funding in 2015, granting a total of NOK 250 million for various projects at Norwegian research institutions.

NOK 206 million was awarded for projects in 2015 through the annual open call for proposals, which takes place each year in October. Awards were publically announced at events held at the Oslo University Hospital, the University of Oslo, the University of Bergen, and the Norwegian University of Science and Technology in Trondheim, as well as at a smaller events held at the Norwegian Cancer Society’s district office in Tromsø. At these events it was emphasised that research funds granted by the Norwegian Cancer Society were not a gift, but rather an investment for better cancer treatment in the future. It was therefore important that both a donor and a recipient/patient participated in each of the events. Personally adapted cancer treatment was still an important priority
area for 2015, and we granted funding for 14 research projects. These funds were raised during the “Combat Against Cancer” campaign.

After receiving a report from NIFU (Nordic Institute for Studies in Innovation, Research and Education) regarding the Norwegian Cancer Society’s role as a research funding agency, the Board began a process in 2015, to change the structure and model for the granting of research funds. Central elements include increased awareness of possible conflicts of interests, simplified administrative routines, and a broader professional focus in the awards for research. Work to develop better models for awarding research funds will continue in 2016.

In 2015, the King Olav V Cancer Research Prize of NOK 1 million was awarded to Professor Rolf Bjerkvig at the University of Bergen, who accepted the prize for his ground-breaking research on brain tumours.

As part of the Norwegian Cancer Society’s focus on health and ethnic minorities, NOK 6.8 million was, in 2015, awarded to three projects that dealt with issues associated with immigrants and cancer.

From good research to better treatment – important investments
The Norwegian Cancer Society intends for good research to benefit the patient, in the form of improved treatment. Unfortunately, the development of a promising product often comes to a standstill due to lack of funding. In 2015, the Norwegian Cancer Society collaborated with the Research Council of Norway on a call for proposals for innovative projects in the field of cancer research. The total financial budget for the call was NOK 18.66 million. The Research Council’s programmes FORNY2020 and BIOTEK2021 provided the remaining funding. This call for proposals was sent to University departments for transfer of technology, or TOTs, and a total of seven projects received grants.

The Norwegian Cancer Society’s public reputation
In 2015, the Norwegian Cancer Society confirmed its good public reputation. In a 2015 profile survey for Norwegian agencies and organisations, carried out by Ipsos MMI each year, the Norwegian Cancer Society ranked high, as it has done in previous years. Among those surveyed, 85 per cent had a positive impression of the Norwegian Cancer Society, which is 2 percentage points higher than in 2014. The Norwegian Cancer Society was in 2015 evaluated as the organisation with the strongest brand among 100 Norwegian organisations, sports and sport profiles.

In 2015, the Norwegian Cancer Society was also an important trailblazer, and a frequently used source for all cases involving cancer. There were approx. 5000 press reports about the Norwegian Cancer Society in 2015, and our website krefeforeningen.no had more than 1 million visitors. We continually have contact with patients, family, and members of the public through social media. The Norwegian Cancer Society’s Facebook page has more than 230,000 followers.

Political advocacy, public education and prevention
In 2015, the Norwegian Cancer Society was successful in gaining support for several important issues. In February, Bent Høie, the Minister of Health and Care Services, together with the Secretary General of the Norwegian Cancer Society, presented a proposal for a standardised and ad-free tobacco packaging. Tobacco packages are like small advertising posters, which strongly appeal to young people. The objective of ad-free tobacco packaging is to prevent another generation from becoming addicted to tobacco. The Norwegian Cancer Society will continue to offer its expertise in assisting the government in these efforts, where the goal is to introduce ad-free packages sometime in 2016.
The introduction of clinical care pathways also represents a milestone in the Norwegian Cancer Society's advocacy efforts. The Norwegian Cancer Society has been involved in the design and implementation of clinical pathways, i.e. through participation in professional groups. In 2015, 28 different cancer diagnoses were each assigned their own assessment and treatment manuals. Early results indicated that approx. 7 out of 10 patients included in a clinical care pathway had received treatment by a specified date. This shows that we are on our way towards ensuring safer treatment for Norwegian cancer patients, but there is still a need for continued efforts in this area.

In addition to political advocacy to expand the supply of free HPV vaccines, the Norwegian Cancer Society has been working to reverse the trend of young women who choose not to get pap smears, which can test for cervical cancer. In collaboration with the women's magazine “Det Nye” and a cervical cancer patient, we launched a campaign called #sjekkdeg (checkyourself), with the purpose of encouraging more women between the ages of 25 and 29 to get pap smears. This message reached more than one million users through the use of social media, and statistics from the Cancer Registry show a clear increase in the number of pap smears among women in this target group. For the first time in 20 years, there has been a marked increase in both attendance and coverage.

As part of preventive public health efforts, the Norwegian Cancer Society launched a project in 2015 called Ad Detectives. Here we wanted to draw attention to ads for unhealthy food products directed at children. More than 350 school children all across Norway were Ad Detectives in 2015. This is how we are able to determine the way in which children experience the impact of advertising. The goal was to change the law, by demanding that the marketing ban be expanded to encompass the arrangement and packaging of unhealthy food products. This project has awakened interest from authorities, the industry and the Consumer Ombudsman.

**Voices of the Norwegian Cancer Society's users make themselves heard**

The Norwegian Cancer Society is working to ensure that the development of services and new technology in the health and care sector to a greater extent becomes user-controlled. This is how we create patient-oriented health services. The Norwegian Cancer Society's advocacy work is aimed at collecting user experiences, opinions and perspectives wherever policies are formulated and strategies are planned, and where measures are implemented in the various public services. For instance, in 2015, the Secretary General became a member of the National Council for Priority Setting in Health Care Services, the national steering One Citizen – One Record and the council for the HelseOmsorg21 strategy process. The Norwegian Cancer Society also provides advice and support for user representatives from the health authorities and NAV (Norwegian Labour and Welfare Administration).

The Norwegian Cancer Society participates in approx. 150 boards, councils, committees, and working groups on a local, national and global level.

**Services for patients and their families all over the country**

The Municipal Cancer Coordinator is still our most important initiative in the area of cancer care, and 2 out of 3 residents had access to a cancer coordinator in 2015. Cancer coordinators act as guides through a complicated public system, and offer cancer patients practical assistance in obtaining access to various services they might need. The Norwegian Cancer Society will grant approximately NOK 200 million
MARCUS AND MARTINUS joined the Combat Against Cancer at the Vinterlyd (Winter Sound) concert tour, organised in collaboration with Radio P4.

BICYCLE RACE Granfondo Don Pedro with Dag Erik Pedersen in the lead brought in NOK 1 million in 2015.
over a period of eight years (2012–2020), and NOK 35 million in 2015. This helps to finance 123 positions for staff that will offer assistance to cancer patients and their families in 200 municipalities and districts. A model for stepping up municipal services was implemented in 2015, and 95% of all municipalities chose to continue this scheme. The cancer coordinator initiative was also included in the Norwegian National Cancer Strategy from 2015, with the goal to “establish cancer coordinator services in all municipalities”.

Varde Centres offer a variety of services, from nutritional advice to legal assistance, thereby reinforcing their position as an important meeting place for cancer patients and their families. In cooperation with health authorities, the Norwegian Cancer Society now has as many as seven such centres, and is represented in all parts of the country. We made this service more widely known through our campaign “Your Cup is Ready”. In 2015, these Varde Centres had 34,000 visitors, with an increase from 23,700 visitors in 2014.

The Cancer Line is a service for those who need to talk to someone about cancer, or who have questions concerning cancer symptoms, treatment, follow-up, and also consequences of cancer. In 2015, the Cancer Line responded to around 15,000 calls. Those who contact the Cancer Line can also receive assistance from Norwegian Cancer Society social workers and lawyers, as part of the Norwegian Cancer Society Rights Service.

Volunteers – our cornerstone
Volunteers are involved in a growing number of Norwegian Cancer Society activities. The commitment shown by our 25,000 volunteers contributes towards an even greater involvement in the cancer cause and in the Norwegian Cancer Society in local communities all over the country.

The Norwegian Cancer Society provides legal services which in 2015 included 65 volunteer lawyers who offered legal advice to cancer patients and their families at Varde Centres all over the country. Norwegian Cancer Society volunteers fill important roles in patient and family services. Treffpunkt (The Meeting Place) has now been established in 31 locations in Norway. Here children and teenagers between the ages of 6 and 16, who have family members with cancer, have the opportunity to talk with one another and with adult leaders. The Temakafé (Theme Café) offers a place for those affected by cancer to get together, and have a coffee and a chat about topics that may be about cancer, but sometimes also about history, culture or politics. In 2015 these cafés were established in 35 locations around the country.

The Norwegian Cancer Society and the rest of the world
Throughout 2015, the Norwegian Cancer Society continued its efforts to highlight cancer and other non-communicable diseases (cardiovascular diseases, diabetes and chronic lung diseases) on national and international health and development policy agendas. In 2015, by virtue of her position as board member, the Secretary General held several central roles in the Union for International Cancer Control (UICC).

The Norwegian Cancer Society were pleased to receive recognition in the form of thanks from the Norwegian UN delegation for excellent contributions during the UN negotiations in 2015, which involved a framework for financing a sustainable development. Norway led these negotiations and presented several proposals from the Norwegian Cancer Society in a plenary session, including text suggestions for the tobacco tax section, which according to the UN delegation, was one of the key factors in determining the results.
The Norwegian Cancer Society heads the European branch of UICC’s international legal network, the “McCabe network”, which shares and develops legal knowledge to benefit the cancer cause. In 2015, the Norwegian Cancer Society, in collaboration with the Ministry of Health and Care Services, organised a workshop on standardised tobacco packaging for lawyers from European public and volunteer sectors.

The Norwegian Cancer Society continued, in 2015, its support for a project for early diagnosis and treatment for breast cancer in Peru, in collaboration with the Breast Cancer Association. The project involves the training of local health personnel, to improve their ability to carry out clinical examinations.

The Norwegian Cancer Society supports the efforts of the Global Alliance for Vaccines and Immunisation, GAVI, and its global programme for HPV vaccinations for the prevention of cervical cancer. The Secretary General participated in an expert panel appointed by the World Health Organisation (WHO) which advises authorities on how to cooperate with the private sector in their work regarding non-communicable diseases.

Campaigns and visibility
Major campaigns including “Combat Against Cancer”, “Pink Ribbon”, and “Men and Cancer” were all carried out in 2015. Around 22,500 door-to-door fundraisers managed to collect NOK 37.1 million for research on personally adapted treatment in the campaign “Combat Against Cancer” (Krafttak mot kreft).

The Norwegian Cancer Society carried out the solidarity and informational Pink Ribbon campaign, in collaboration with the Breast Cancer Association. The theme for 2015 was “Living with incurable breast cancer”. In 2015, more than 1500 people gathered for the world’s longest pink luncheon table in downtown Oslo, organised by the Pink Ribbon campaign. Similar luncheon events were held in Bodø, Bergen and Trondheim in solidarity with those living with incurable breast cancer. The Pink Ribbon campaign in 2015 was the most visible campaign so far, where the Society was mentioned in 890 media reports, an increase of 28.5 per cent from 2014. Supporters and cooperative partners collected altogether NOK 27.1 million for the breast cancer cause. November has been designated the “Men’s Month”. Again the Norwegian Cancer Society’s message to men was as simple as it was important: “Learn about the warning signs of cancer”. The 2015 campaign drew slightly less attention than in the previous year. About 15,500 men participated in the moustache campaign, “Movember”, compared with 22,000 participants in 2014. The funds that were raised went to research for prostate cancer.

Administration
The Norwegian Cancer Society is a member of the employer association Virke (Enterprise Federation of Norway), and has been certified as an eco-enterprise by the Eco-Lighthouse Foundation. None of the Norwegian Cancer Society’s business activities has a harmful impact on the external environment.

The Norwegian Cancer Society is an Inclusive Workplace enterprise (IA), and works actively to prevent and reduce sick leave absence, encourage workplace attendance and improve the working environment, as well as preventing employment exclusion and dropout. In 2015 we established “walk meetings” as a preventive and health-promoting initiative. Sick leave absence at the Norwegian Cancer Society was 5.3 % in 2015, compared with 4.3 % the previous year.

On 10 April 2015, the Norwegian Cancer Society headquarters and the district office in Oslo moved to a new location on Kongens gate 6, Sjøfartsbygningen (the
Several well-known women joined the #SJEKKDEG (Check yourself) campaign team, including Jenny Skavlan who encouraged other young women to book appointments for pap smears.

ANNE LISE RYEL AND BENT HØIE launched a proposal for standardised and ad-free tobacco packaging.
Maritime Building). This building has been adapted to ensure the best possible interaction between all sections of the organisation, and an internal survey showed that an additional 30% of employees now feel that our new location contributes positively to our good working environment.

Credibility, openness, respect and commitment are values that guide us and steer our work, and that form the basis of our common culture and identity.

Our working environment shall be one distinguished by diversity and expertise. Women make up 77% of our staff, compared with 78% in 2014. The year 2015 ended with a turnover of 6.7% which was slightly lower than for 2014. The Norwegian Cancer Society had 184 full-time positions throughout 2015. Cooperation within the organisation and with union representatives has been characterised by openness and constructive dialogue. No serious injuries or accidents were reported in the workplace in 2015.

Financial foundation
The Norwegian Cancer Society’s accounts have been prepared in accordance with the Accounting Act of 1988, and in compliance with the NRS (F) accounting standards “Generally accepted accounting principles for non-profit organisations”.

Results of annual activities
In 2015, activities resulted in a deficit of NOK 48.9 million, compared with a surplus of NOK 3.6 million in 2014. Fundraising and donations increased by NOK 25.3 million compared with 2014. Use of funds to generate revenue increased by NOK 14.9 million, and we spent NOK 25.8 million more on core activities in 2015 than in 2014. Financial revenue was NOK 39.8 million in 2015, compared with NOK 74.5 million in 2014.

Income
The Norwegian Cancer Society’s work is primarily funded through fundraising efforts, bequests and support from the Norwegian National Lottery. Bequests were one of the largest sources of income in 2015, accounting for NOK 139.7 million. We had more than 31,000 regular donors who gave us NOK 34.7 million. We received NOK 60.8 million in response to donor letters, and NOK 23.6 million in memorial gifts (donations given in memory of a deceased person). We received NOK 69 million in 2015. There will be major changes in the allocation of lottery funds after 2017, with significant financial consequences for the Norwegian Cancer Society.

In 2015 the Norwegian Cancer Society received NOK 3.6 million in government grants, as well as VAT compensation worth NOK 28.3 million. The Norwegian Cancer Society does not engage in telemarketing.

Use of funds
The collection rate was 79.6 per cent in 2015, decreasing from 81.8 per cent in 2014. The Norwegian Cancer Society is registered with the Norwegian Control Committee for Fundraising, and meets the standard requirements stipulating that the collection rate must be at least 65 per cent. Income from bequests, campaigns and other donations was higher in 2015 than in 2014, with an increase in the use of funds. Overhead costs, i.e. costs that cannot be directly linked to any specific activity, totalled NOK 66.7 million, and were allocated to fundraising expenses, certain core activities, and administrative costs relative to the number of full-time positions associated with the activity. The Norwegian Cancer Society allocated NOK 496.3 million to its core activities. This represents 84.3 per cent of all allocated funds, while the equivalent figure was 85.9 per cent in 2014. Administrative costs that cover some of the administrative functions and some of the expenditures of the Secretary
General and Assistant Secretary General represent 1.5 per cent of allocated funds.

Finance
The Norwegian Cancer Society invests its assets based on advice from its own finance committee and from professionals who volunteer their time. The goal is to strike a balance between a satisfactory return while also ensuring that funds are invested with caution and respect for the funds that have been raised, with regard to security, liquidity and risk diversification.

In 2015, the Norwegian Cancer Society’s externally managed funds totalled NOK 901.8 million, which can be broken down into NOK 458.7 million in equity funds and NOK 443.1 million in interest rate instruments. The return on these externally managed funds was NOK 37.5 million in 2015. This is equivalent to a return of 4.9 per cent. In comparison, the return in 2014 was NOK 71.4 million, equivalent to a return of 8.5 per cent. NOK 30.1 million was taken out of the portfolio during the course of 2015.

From 2001 to 2015, the average annual return on the Norwegian Cancer Society’s managed funds was 5.5 per cent.

In order to reduce the risk associated with investments in shares/equity funds and interest rate instruments, the Norwegian Cancer Society has chosen to use seven different managers. We had a distribution of equity funds and interest rate instruments of 51 per cent and 49 per cent respectively by the end of 2015. The distribution of Norwegian and foreign equity funds was 44 per cent and 56 per cent respectively. Share investments in foreign equity funds are not hedged against the Norwegian Krone. The funds that the Norwegian Cancer Society has invested in are quoted in Norwegian kroner and have shareholdings in local currencies in large parts of the world. A reduced level of risk is achieved through exposure to several currencies. The Norwegian Cancer Society has ethical guidelines in place for financial management. This means that we do not invest in businesses or corporations that produce tobacco. Furthermore, we follow the “Guidelines for observation and exclusion from the Government pension fund overseas investment universe”.

Liabilities
The Norwegian Cancer Society has granted money for projects that are due for payment after the end of 2015. This funding obligation of NOK 533.1 million has been classified as a liability on the balance sheet. Other liabilities are primarily related to accounts payable, taxes and payroll obligations.

Liquidity
In 2015 our liquidity reserves were reduced by NOK 3.1 million. At the end of 2015 the Norwegian Cancer Society had NOK 201.2 million cash in bank. The cash in bank was reduced by NOK 10.4 million during 2015, and portfolio securities increased by NOK 7.3 million. Unpaid grants, classified as liabilities on the balance sheet, increased by NOK 45.9 million during 2015.

Equity
It is important for the Norwegian Cancer Society to have sufficient equity to manage any future loss of revenue. The Norwegian Cancer Society shall be a long-term, reliable organisation with a robust capital, so that we are in a position to take on major national initiatives in the field of cancer work. Our cooperative partners can and should feel secure in knowing that the Norwegian Cancer Society is able to follow up its obligations with regard to cancer research and cancer care. The Norwegian Cancer Society has also had a major boost in the form of municipal cancer coordinator positions and strategic research projects,
including seed investments. Funds have been allocated to all projects that the Norwegian Cancer Society has contributed towards, so that funding of these projects will be secured regardless of future income status.

**Continuing operations – “going concern assumption”**

Accounts have been prepared under the going concern assumption, and the Board confirms that the requirements for this assumption have been met.

**Other issues**

To the best of the Board's knowledge, no circumstances have arisen after the end of the financial year that have significance for the organisation's position and results.

**Allocation of results**

The Board proposes the following administration of this year’s results – a deficit of NOK 48.9 million:

- Transfer from, thereby reducing, other equity: NOK 96.4 million
- Transfer to, thereby increasing equity with self-imposed restrictions: NOK 26.8 million
- Transfer to, thereby increasing equity, with externally imposed restrictions: NOK 20.7 million

**Foundations**

The Norwegian Cancer Society administers and/or participates in 17 foundations that promote the cancer cause.

After eight years as Chairman of the Norwegian Cancer Society, Paul Hellandsvik resigned in May 2015. The Board of Representatives selected Gunn-Elin Aa Bjørneboe as his successor.

Oslo, 28 April 2016

Gunn-Elin Aa. Bjørneboe
Chairman

Carl Otto Løvenskiold
Deputy Chairman

Tone Nordøy

Lars A. Akslen

Anine Kierulf

Grete Wennes

Tord Dale

Else Støring
Staff representative

Anne Lise Ryel
Secretary General
Revenue for 2015

- VAT compensation 6 % (NOK 28 million)
- Funds from Norsk Tipping (Norwegian National Lottery) 14 % (NOK 69 million)
- Membership fees 5 % (NOK 23 million)
- Grants and donations from foundations 3 % (NOK 17 million)
- Bequests 28 % (NOK 140 million)
- Memorial gifts 5 % (NOK 24 million)
- Donations and funds raised from private individuals 32 % (NOK 162 million)
- Donations from businesses and sponsor revenue 6 % (NOK 32 million)
- Public grants 1 % (NOK 4 million)

Use of funds

- Core activities 84 % (NOK 496 million)
- To create income 14 % (NOK 84 million)
- Administration costs 2 % (NOK 9 million)

Use of funds for core activities

- Research 53 % (NOK 263 million)
- Information/health education 11 % (NOK 53 million)
- Cancer care 30 % (NOK 148 million)
- Community contact 2 % (NOK 9 million)
- International work 1 % (NOK 5 million)
- Preventive work 3 % (NOK 18 million)
KONG OLAV V CANCER RESEARCH AWARD 2015
Professor Rolf Bjerkvig received the award for his work on brain tumours and basic science and translational research for clinical application. He has distinguished himself as a strong research leader, has made significant contributions to Norwegian cancer research. Bjerkvig has also received considerable international recognition. He has been awarded a number of international prizes and has been offered professorships abroad. The prize money in the amount of NOK 1 million was presented in the Gamle Festsal at the University of Oslo on 8 June.
The Norwegian Cancer Society cooperates with organisations representing cancer patients and their families.

- **Norilco**
  - www.norilco.no

- **Barnekreft foreningen**
  - www.barnekreftforeningen.no

- **Brystkreftforeningen**
  - www.brystkreftforeningen.no

- **Sarkomer**
  - www.sarkomer.no

- **Carcinor**
  - www.carcinor.no

- **Gynkreftforeningen**
  - www.gynkreftforeningen.no

- **Blodkreftforeningen**
  - www.blodkreftforeningen.no

- **Munn- og halskreftforeningen**
  - www.munnoghalskreft.no

- **PROFO**
  - Prostatakreftforeningen
  - www.prostatakreft.no

- **Lungekreftforeningen**
  - www.lungekreftforeningen.no

- **Lymfekreftforeningen**
  - www.lymfekreft.no

- **Hjernesvulstforeningen**
  - www.hjernesvulst.no

- **Kreftomsorg Rogaland**
  - www.kreftomsorg.no

- **UNGkreft**
  - www.ungkreft.no

- **Følekkreftforeningen**
  - www.følekkreft.no

A volunteer organisation for cancer patients in Rogaland County.